Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance

Exact Sciences Corp.EXAS on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst consensus loss estimate of 38 cents.The company reported quarterly sales of $706.78 million, up 11% year over year on a reported and core revenue basis, beating the consensus estimate of$ 688.64 million.Screening revenue was $540 million, an increase of 14%, and Precision Oncology's revenue was$ 166.8 million, an increase of 2% or 4% on a core revenue basis."Our s ...